TNYA is a cash-backed, catalyst-rich clinical biotech with two Phase 1b/2 cardiovascular gene-therapy programs and a revived TN-301 option. The opportunity is real, but the equity remains binary because pivotal-trial alignment, Nasdaq bid compliance and future dilution all sit in front of commercialization.
rNPV probability assumptions are below Phase 2/3 norms because patient count remains small and neither TN-201 nor TN-401 has pivotal-trial alignment yet. The implied ex-cash pipeline value is about $172M versus current EV near $82M. Cash-adjusted cross-check: applying 1.8x current EV to the current $82M EV gives about $147M pipeline value plus $74M net cash, or about $0.99 per share before dilution, within 10% of the $1.10 base case. Analyst consensus is much higher at $3.20; the gap reflects sell-side use of larger peak-sales and probability assumptions. A $100M change in aggregate pipeline rNPV moves FV by about $0.45 per share. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| TN-201 HCM rNPV | 24% probability x $1.6B peak sales x 24% rNPV/peak factor = $92M / 224.23M shares | +0.41 |
| TN-401 ARVC rNPV | 22% probability x $0.9B peak sales x 30% rNPV/peak factor = $59M / 224.23M shares | +0.26 |
| TN-301 HDAC6 option | 10% probability x $1.2B peak sales x 30% rNPV/peak factor = $36M / 224.23M shares | +0.16 |
| Alnylam collaboration option | 5% probability x $250M near/mid-term milestone basket = $12.5M / 224.23M shares | +0.06 |
| Net cash bridge | ($78.09M cash - $3.95M debt) / 224.23M shares | +0.33 |
| Dilution reserve | Base case assumes roughly 35M future financing shares at sub-$1 to $1.25 range before pivotal clarity | -0.12 |
| FV base case | 0.41 + 0.26 + 0.16 + 0.06 + 0.33 - 0.12 | 1.10 |
Short interest is moderate, not extreme. It can amplify positive Q4 clinical news, but the larger issue is financing risk because net cash covers only about four to five quarters of planned operations.
| Item | FY2023 | FY2024 | FY2025 | TTM Jun. 2026 | Guidance 2026 |
|---|---|---|---|---|---|
| Collaboration revenue | $0.0M | $0.0M | $0.0M | $1.34M | N/D - milestone timing |
| Operating income | -$131.2M | -$115.9M | -$93.3M | -$105.9M | Loss expected |
| Net loss | -$124.1M | -$111.1M | -$90.6M | -$103.1M | Loss expected |
| Operating cash flow | -$102.1M | -$90.5M | -$68.3M | -$52.3M | Lower burn after restructuring |
| Cash and investments | $104.6M | $61.4M | $100.5M | $78.1M | Through Q3 2027 |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 0.00 | 0.00 | 0.00 | 0.23 | 1.11 |
| Gross margin % | N/M | N/M | N/M | 100% | 100% |
| Net loss ($M) | -23.3 | -20.3 | -20.2 | -19.3 | -43.4 |
| End-of-period cash ($M) | 71.7 | 56.3 | 100.5 | 80.9 | 78.1 |
Business model - cardiovascular genetic medicines
TN-201 - MYBPC3 HCM Phase 1b/2; $1.6B modeled peak sales ramping Lead AAV9 gene therapy for MYBPC3-associated HCM. Six evaluable patients showed improvements across cardiac remodeling and symptoms; additional interim data and regulatory update are expected in Q4 2026. TN-401 - PKP2 ARVC Phase 1b/2; $0.9B modeled peak sales ramping AAV9 gene therapy for PKP2-associated ARVC. Interim RIDGE-1 data showed mean PVC reductions across six patients and no dose-limiting toxicities; pivotal alignment remains the next value gate. TN-301 - HDAC6 inhibitor Phase 1 completed; patient trial planned 2H 2027 to prove Small molecule option for HFpEF, DMD and related diseases. Preclinical DMD data are encouraging, but human proof-of-activity in patients is still ahead.
Legal, regulatory and risk analysis
SWOT analysis
- +Two lead gene-therapy programs with human Phase 1b/2 data.
- +Net cash position and low debt support near-term execution.
- +EMA PRIME and FDA designations strengthen regulatory dialogue.
- +Alnylam collaboration validates discovery capabilities and adds optional milestones.
- −No approved product and negligible collaboration revenue.
- −Runway only through Q3 2027, not through pivotal completion.
- −Very high dilution over the last year.
- −Sub-$1 share price creates listing and market-structure pressure.
- →Q4 2026 data and regulatory updates can re-rate the pipeline.
- →TN-301 gives a non-gene-therapy option with broader disease reach.
- →Partnership or non-dilutive funding could extend runway.
- →A credible pivotal path for either TN-201 or TN-401 would move rNPV materially.
- !Gene-therapy safety concerns can emerge late and affect the whole platform.
- !Clinical readouts may not translate into registrational endpoints.
- !Future equity raises could occur before major value inflection.
- !Competitive genetic-medicine programs can narrow the strategic window.
Summary by assessment area
- Cash covers the next catalyst cycle but not a full late-stage development plan.
- Debt is low; dilution is the real capital-structure issue.
- Human signals are encouraging but based on small open-label cohorts.
- Regulatory alignment is the key next proof point.
- Base FV of $1.10 is above the current $0.695 close, and analyst targets are much higher.
- Bear case remains close to cash-burn floor if Q4 data disappoint.
Sources: Tenaya Therapeutics Q2 2026 financial results and business update dated 2026-08-05; Tenaya Therapeutics Q1 2026 and FY2025 result releases; Tenaya Therapeutics TN-201 MyPEAK-1 interim data release dated 2026-06-03; TN-401 RIDGE-1 interim data release dated 2026-05-15; Tenaya September 2026 investor-conference release; Tenaya 2026 Form 10-Q filed 2026-08-05; SEC Form 10-K for FY2025; StockAnalysis TNYA overview, statistics, financials and forecast pages; Investing.com, FT.com and ChartExchange price checks; MarketBeat short-interest data; Form4.app/Form4API/Arkolith insider-transaction summaries. Market data - last verified close 2026-09-03: TNYA $0.6953, market cap about $155.9M, 52W range $0.5316-$2.3500, 224.23M shares outstanding. Short interest: 21.10M shares, about 9.41% of shares outstanding / 9.97% of float, 11.33 days to cover. Analyst consensus: StockAnalysis $3.20 average target from 7 analysts as checked 2026-09-04; latest visible individual targets include Canaccord $5 on 2026-08-07 and LifeSci $4 on 2026-08-06. Governance/litigation check: searches found no fresh material class action, SEC investigation or short-seller report; recent named insider sales were small and below the $500K disclosure threshold used in this report. This document is for informational purposes only and does not constitute financial or investment advice.